Skip to main content

Table 5 Adjusted odds of remaining in the study at M6 by variables found to be significant in univariate regression analysis

From: The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Significant variables Multivariate regression analysis
AORa 95% CIb P
Use of opioid
  N  
  Y 0.62 0.46, 0.85 0.003
Use of antidepressant    
  N  
  Y 1.42 0.98, 2.07 0.061
Use of anti-seizure
  N  
  Y 1.91 1.30, 2.81  < 0.001
WHOQOL—psychological (baseline)
  < 54  
  ≥ 54 1.43 1.08, 1.90 0.013
Preferred type of cannabis
  CBD  
  THC 0.87 0.59, 1.27 0.5
  No preference 1.16 0.82, 1.63 0.4
Primary method of use
  Inhaled  
  Orally ingested 0.87 0.64, 1.19 0.4
Enrollment period
  Enrolled prior to 17 April 2018 (M6 would be pre-legalization)  
  Enrolled between 17 April and 15 July 2018 (M6 would be post-legalization) 0.28 0.18, 0.41  < 0.001
  1. aAOR  Adjusted odds ratio, bCI Confidence interval